종양학 바이오시밀러 시장 : 약제 클래스별, 암종별, 유통 채널별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2023-2030년)

Oncology Biosimilars Market with COVID-19 Impact Analysis, By Drug Class, By Type of Cancer, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030

US $ 3,250 ￦ 4,535,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 4,650 ￦ 6,488,000

PDF (5 User License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,650 ￦ 7,884,000

PDF & Excel (Enterprise User License)

PDF & Excel 보고서를 동일 기업 내 모든 사용자가 사용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

보고서 주요 내용

종양학 바이오시밀러 시장 규모는 2022년 42억 12만 달러로 2023년부터 2030년까지 CAGR 10.67%로 확대

종양학 바이오시밀러 시장 - 시장 역학:

• 암 유병률 증가.
• 암 발병률 증가는 종양학 바이오시밀러 시장을 견인하는 주요 요인입니다. 국제암연구소(IARC)는 2040년까지 전 세계적으로 1,630만 명이 암으로 사망하고 2,750만 명이 새롭게 암 진단을 받을 것으로 예상하고 있습니다. 정상 세포는 일반적으로 전암 병변에서 암이 시작되면 악성 종양으로 변하는 다단계 과정을 거칩니다. 노년층은 정상적인 위험의 축적에 더해 세포 복구 시스템의 효과가 저하되는 경우가 많습니다. 흡연, 음주, 거친 식습관, 불규칙한 생활, 대기오염은 모두 암 발생 가능성을 높입니다.

종양학 바이오시밀러 시장 - 세분화 분석:

• 세계 종양학 바이오시밀러 시장은 약제 클래스별, 암종별, 유통 채널별, 지역별로 구분됩니다.
• 약물 종류에 따라 단클론항체, G-CSF, 조혈제, 기타로 분류되며, G-CSF의 높은 시장 점유율은 암 치료 후 백혈구 회복을 돕기 위해 화학요법 후 G-CSF가 널리 사용되는 결과입니다. 과립구 콜로니 자극 인자(G-CSF)는 필그라스팀, 레노그라스팀, 장시간 작용하는 필그라스팀, 페그필그라스팀 등 다양한 형태가 있습니다.
• 유방암, 폐암, 위암, 전립선암, 자궁경부암, 혈액암, 뇌종양, 기타. 모든 악성 종양 중 유방암 환자의 비율이 전 세계적으로 가장 높기 때문에 유방암 분야가 시장을 독점하고 있습니다. 유방암의 위험은 연령, 비만, 알코올 중독, 담배 사용, 폐경 후 호르몬 치료, 방사선 노출, 가족력 등 많은 변수에 의해 증가합니다.

종양학 바이오시밀러 시장 - 지리적 인사이트:

지리적으로 이 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카로 나뉩니다. 이 지역들은 사업 운영 국가에 따라 더 세분화됩니다. 아시아태평양은 신흥 시장으로, 특히 한국, 중국, 인도가 암 바이오시밀러 분야에서 두각을 나타내고 있습니다. 인구가 많고, 건강 지향적 성향이 강하며, 의료비 증가와 제조 비용의 감소로 인해 시장의 잠재력을 반영하고 있습니다.

종양학 바이오시밀러 시장 - 경쟁 상황:

회사들은 기업 사이트, E-Commerce 사이트, 소매업체, 유통업체, 최종 소비자 등 다양한 채널을 통해 제품을 판매합니다. 제품 제조업체들은 제품 비용, 성능, 제품 제조, 유통 채널, 평판, 가용성 등 다양한 측면에서 경쟁하고 있습니다. 기업이 도달 범위를 강화하고 시장 점유율을 확대하기 위해 사용하는 주요 방법에는 신제품 출시, 유통망 개척, R&D 비용, M&A 등이 있습니다. 예를 들어, 2022년 5월 Biocon Biologics와 Viatris가 제조한 세 번째 암 바이오시밀러인 Abevmy(베바시주맙)가 캐나다에서 출시될 예정입니다.

목차

제1장 종양학 바이오시밀러 시장 개요

• 조사 범위
• 시장 추정 연수

제2장 주요 요약

• 시장 내역
• 경쟁 인사이트

제3장 종양학 바이오시밀러 주요 시장 동향

• 시장 성장 촉진요인
• 시장 성장 억제요인
• 시장 기회
• 향후 시장 동향

제4장 종양학 바이오시밀러 업계 조사

• PEST 분석
• Porter's Five Forces 분석
• 성장 전망 매핑
• 규제 체계 분석

제5장 종양학 바이오시밀러 시장 : COVID-19의 영향 분석

• 신종 코로나바이러스 감염증 이전의 영향 분석
• 신종 코로나바이러스 감염증 후의 영향 분석

제6장 종양학 바이오시밀러 시장 상황

• 종양학 바이오시밀러 시장 점유율 분석, 2022년
• 주요 제조업체별 내역 데이터
  • 기존 기업 분석
  • 신흥 기업 분석

제7장 종양학 바이오시밀러 시장 - 약제 클래스별

• 개요
  • 약제 클래스별 부문 점유율 분석
  • 단클론항체
  • G-CSF
  • 조혈제
  • 기타

제8장 종양학 바이오시밀러 시장 - 암 종류별

• 개요
  • 암 종류별 부문 점유율 분석
  • 유방암
  • 폐암
  • 위암
  • 전립선암
  • 자궁경부암
  • 혈액암
  • 뇌종양
  • 기타

제9장 종양학 바이오시밀러 시장 - 유통 채널별

• 개요
  • 판매 채널별 부문 점유율 분석
  • 소매 약국
  • 병원 약국
  • 온라인 약국

제10장 종양학 바이오시밀러 시장 - 지역

• 서론
• 북미
  • 개요
  • 북미의 주요 제조업체
  • 미국
  • 캐나다
• 유럽
  • 개요
  • 유럽의 주요 제조업체
  • 독일
  • 이탈리아
  • 영국
  • 프랑스
  • 러시아
  • 네덜란드
  • 스웨덴
  • 폴란드
  • 기타
• 아시아태평양(APAC)
  • 개요
  • 아시아태평양의 주요 제조업체
  • 인도
  • 중국
  • 일본
  • 한국
  • 호주
  • 태국
  • 인도네시아
  • 필리핀
  • 기타
• 라틴아메리카
  • 개요
  • 라틴아메리카의 주요 제조업체
  • 브라질
  • 멕시코
  • 아르헨티나
  • 콜롬비아
  • 기타
• 중동 및 아프리카
  • 개요
  • 중동 및 아프리카의 주요 제조업체
  • 사우디아라비아
  • 아랍에미리트
  • 이스라엘
  • 터키
  • 알제리
  • 이집트
  • 기타

제11장 주요 벤더 분석 - 종양학 바이오시밀러 업계

• 경쟁 대시보드
• 기업 개요
  • Teva Pharmaceuticals
  • STADA Arzneimittel AG
  • Shanghai Henlius Biotech
  • Sandoz(Novartis)
  • Samsung Bioepis
  • Pfizer
  • Pfenex Inc.
  • Mylan
  • Innovent Biologics
  • Dr. Reddy's Laboratories
  • Celltrion Healthcare
  • Biocon
  • Apotex
  • Amgen
  • Accord Healthcare

제12장 애널리스트의 전방위 전망

ksm

영문 목차

영문목차

REPORT HIGHLIGHT

Oncology Biosimilars Market size was valued at USD 4,200.12 Million in 2022, expanding at a CAGR of 10.67% from 2023 to 2030.

Oncology biosimilars are biological medicines created to be strikingly comparable to and functionally equal to the oncology reference biologics, which are currently available in pharmaceuticals. These biosimilars are created to offer affordable cancer therapy choices. They go through thorough comparative tests to show that they are comparable in terms of safety, quality, and efficacy. Oncology biosimilars seek to improve patient access to essential cancer treatments while also perhaps lowering healthcare costs by providing therapeutic results that are equivalent to those of the unique oncology biologics. A comprehensive regulatory review is required for their approval to guarantee patient safety and maintain cancer treatment requirements.

Oncology Biosimilars Market- Market Dynamics:

• Increasing prevalence of cancer.

• The rising incidence of cancer is the primary factor driving the market for oncology biosimilars. The International Agency for Research on Cancer (IARC) predicts that by 2040, there would be 16.3 million cancer-related deaths globally and 27.5 million new cancer diagnoses. Normal cells go through a multi-stage process that normally goes from a pre-cancerous lesions to a tumor that is malignant when cancer begins. Aging persons often have less effective cellular repair systems in addition to the normal risk buildup. Smoking, consuming alcohol, adopting a poor diet, leading a life of inactivity, and air pollution all increase the chance of developing cancer.

Oncology Biosimilars Market- Key Insights:

• As per the analysis shared by our research analyst, the global Oncology Biosimilars market is estimated to grow annually at a CAGR of around 10.67% over the forecast period (2023-2030)

• The Oncology Biosimilars industry is projected to grow at a significant rate due to the growing prevalence of cancer

• Based on drug class segmentation, G-CSF was predicted to show maximum market share in the year 2022

• Based on type of cancer, breast cancer was the leading type in 2022

• Based on distribution channel segmentation, hospital retail was the leading type in 2022

• On the basis of region, North America was the leading revenue generator in 2022

Oncology Biosimilars Market- Segmentation Analysis:

• The Global Oncology Biosimilars Market is segmented on the basis of Drug Class, Type of Cancer, Distribution Channel, and Region.

• The market is divided into categories based on Drug Class: monoclonal antibodies, G-CSF, hematopoietic agents, and others. The higher market share of G-CSF is a result of the widespread use of G-CSF after chemotherapy to aid in the recovery of white blood cells following cancer treatment. Granulocyte colony-stimulating factors (G-CSF) are available in a variety of forms, including filgrastim, lenograstim, long-acting filgrastim, and pegfilgrastim.

• The market is divided into categories based on type of cancer: breast cancer, lung cancer, stomach cancer, prostate cancer, cervical cancer, blood cancer, brain cancer, and others. Due to the highest percentage of breast cancer cases globally among all malignancies, the breast cancer sector commands the market. The risk of breast cancer is increased by a number of variables, including age, obesity, alcoholism, cigarette use, postmenopausal hormone treatment, exposure to radiation history, and family history of the disease.

Oncology Biosimilars Market- Geographical Insights:

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. The Asia Pacific region is a developing market, with Korea, China, and India, in particular, making strides with cancer biosimilars. Due to a large population, rising health consciousness, rising healthcare expenditure, and decreased manufacturing costs, they also reflect the market's future potential.

Oncology Biosimilars Market- Competitive Landscape:

Companies sell their products through a variety of channels, including corporate websites, e-commerce websites, retailers, distributors, and end consumers. Products makers compete on a variety of aspects, including product costs, performance, product making, Distribution Channel, reputation, and availability. Some of the primary techniques used by corporations to strengthen their reach and expand their market share include new product launches, distribution network development, R&D spending, and mergers and acquisitions. For instance, May 2022, Abevmy (bevacizumab), the third cancer biosimilar produced by Biocon Biologics and Viatris, has made accessible in Canada.

Recent Developments:

September 2022, Celltrion USA received FDA permission for using its oncology biosimilar vegzelma (bevacizumab-add) to treat six different forms of cancer.

Key features of the study:

• This proposed research study on Oncology Biosimilars market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year

• The report provides the client the latest up-to-date and trending insights about the Oncology Biosimilars market.

• The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Oncology Biosimilars market

• The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Oncology Biosimilars market

• Impact of COVID-19 on Oncology Biosimilars market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Oncology Biosimilars market post-COVID will also be covered.

• In order to give the users of this report a comprehensive view on the Oncology Biosimilars market, we have also included competitive landscape and key innovator analysis for the Oncology Biosimilars market.

• The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.

• The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Oncology Biosimilars market.

• In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.

• The global Oncology Biosimilars market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ONCOLOGY BIOSIMILARS MARKET KEY PLAYERS

• Teva Pharmaceuticals
• STADA Arzneimittel AG
• Shanghai Henlius Biotech
• Sandoz (Novartis)
• Samsung Bioepis
• Pfizer
• Pfenex Inc.
• Mylan
• Innovent Biologics
• Dr. Reddy's Laboratories
• Celltrion Healthcare
• Biocon
• Apotex
• Amgen
• Accord Healthcare

GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY DRUG CLASS

• Monoclonal Antibodies
• G-CSF
• Hematopoietic Agents
• Others

GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY TYPE OF CANCER

• Breast Cancer
• Lung Cancer
• Stomach Cancer
• Prostate Cancer
• Cervical Cancer
• Blood Cancer
• Brain Cancer
• Others

GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY REGION

• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe
• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Oncology Biosimilars Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Oncology Biosimilars Market Snippet by Drug Class
  • 2.1.2. Oncology Biosimilars Market Snippet by Type of Cancer
  • 2.1.3. Oncology Biosimilars Market Snippet by Distribution Channel
  • 2.1.4. Oncology Biosimilars Market Snippet by Country
  • 2.1.5. Oncology Biosimilars Market Snippet by Region
• 2.2. Competitive Insights

3. Oncology Biosimilars Key Market Trends

• 3.1. Oncology Biosimilars Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Oncology Biosimilars Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Oncology Biosimilars Market Opportunities
• 3.4. Oncology Biosimilars Market Future Trends

4. Oncology Biosimilars Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Oncology Biosimilars Market: COVID-19 Impact Analysis

• 5.1. Pre-COVID-19 Impact Analysis
• 5.2. Post-COVID-19 Impact Analysis
  • 5.2.1. Top Performing Segments
  • 5.2.2. Marginal Growth Segments
  • 5.2.3. Top Looser Segments
  • 5.2.4. Marginal Loss Segments

6. Oncology Biosimilars Market Landscape

• 6.1. Oncology Biosimilars Market Share Analysis, 2022
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Oncology Biosimilars Market - By Drug Class

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Drug Class, 2022 & 2030 (%)
  • 7.1.2. Monoclonal Antibodies
  • 7.1.3. G-CSF
  • 7.1.4. Hematopoietic Agents
  • 7.1.5. Others

8. Oncology Biosimilars Market - By Type of Cancer

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Type of Cancer, 2022 & 2030 (%)
  • 8.1.2. Breast Cancer
  • 8.1.3. Lung Cancer
  • 8.1.4. Stomach Cancer
  • 8.1.5. Prostate Cancer
  • 8.1.6. Cervical Cancer
  • 8.1.7. Blood Cancer
  • 8.1.8. Brain Cancer
  • 8.1.9. Others

9. Oncology Biosimilars Market - By Distribution Channel

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
  • 9.1.2. Retail Pharmacies
  • 9.1.3. Hospital Pharmacies
  • 9.1.4. Online Pharmacies

10. Oncology Biosimilars Market- By Geography

• 10.1. Introduction
  • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
• 10.2. North America
  • 10.2.1. Overview
  • 10.2.2. Oncology Biosimilars Key Manufacturers in North America
  • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.2.4. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
  • 10.2.5. North America Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
  • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.2.7. U.S.
    • 10.2.7.1. Overview
    • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.2.7.4. U.S. Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.2.8. Canada
    • 10.2.8.1. Overview
    • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.2.8.4. Canada Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
• 10.3. Europe
  • 10.3.1. Overview
  • 10.3.2. Oncology Biosimilars Key Manufacturers in Europe
  • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
  • 10.3.5. Europe Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
  • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.7. Germany
    • 10.3.7.1. Overview
    • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.7.4. Germany Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.8. Italy
    • 10.3.8.1. Overview
    • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.8.4. Italy Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.9. United Kingdom
    • 10.3.9.1. Overview
    • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.9.4. United Kingdom Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.10. France
    • 10.3.10.1. Overview
    • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.10.3. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.10.4. France Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.11. Russia
    • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.11.3. Russia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.12. Netherlands
    • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.12.3. Netherlands Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.13. Sweden
    • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.13.3. Sweden Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.14. Poland
    • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.14.3. Poland Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.15. Rest of Europe
    • 10.3.15.1. Overview
    • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
• 10.4. Asia Pacific (APAC)
  • 10.4.1. Overview
  • 10.4.2. Oncology Biosimilars Key Manufacturers in Asia Pacific
  • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
  • 10.4.5. Asia Pacific Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
  • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.7. India
    • 10.4.7.1. Overview
    • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.7.3. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.7.4. India Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.8. China
    • 10.4.8.1. Overview
    • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.8.3. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.8.4. China Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.9. Japan
    • 10.4.9.1. Overview
    • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.9.4. Japan Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.10. South Korea
    • 10.4.10.1. Overview
    • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.10.4. South Korea Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.11. Australia
    • 10.4.11.1. Overview
    • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.11.4. Australia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.12. Thailand
    • 10.4.12.1. Overview
    • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.12.4. Thailand Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.13. Indonesia
    • 10.4.13.1. Overview
    • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.13.4. Indonesia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.14. Philippines
    • 10.4.14.1. Overview
    • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.14.4. Philippines Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.15. Rest of APAC
    • 10.4.15.1. Overview
    • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.15.4. Rest of APAC Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
• 10.5. Latin America
  • 10.5.1. Overview
  • 10.5.2. Oncology Biosimilars Key Manufacturers in Latin America
  • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
  • 10.5.5. Latin America Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
  • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5.7. Brazil
    • 10.5.7.1. Overview
    • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.7.4. Brazil Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5.8. Mexico
    • 10.5.8.1. Overview
    • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.8.4. Mexico Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5.9. Argentina
    • 10.5.9.1. Overview
    • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.9.4. Argentina Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5.10. Colombia
    • 10.5.10.1. Overview
    • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.10.4. Colombia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5.11. Rest of LATAM
    • 10.5.11.1. Overview
    • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
• 10.6. Middle East and Africa
  • 10.6.1. Overview
  • 10.6.2. Oncology Biosimilars Key Manufacturers in Middle East and Africa
  • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
  • 10.6.5. Middle East and Africa Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
  • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6.7. Saudi Arabia
    • 10.6.7.1. Overview
    • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6.8. United Arab Emirates
    • 10.6.8.1. Overview
    • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6.9. Israel
    • 10.6.9.1. Overview
    • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.9.4. Israel Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6.10. Turkey
    • 10.6.10.1. Overview
    • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.10.4. Turkey Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6.11. Algeria
    • 10.6.11.1. Overview
    • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.11.4. Algeria Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6.12. Egypt
    • 10.6.12.1. Overview
    • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.12.4. Egypt Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6.13. Rest of MEA
    • 10.6.13.1. Overview
    • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.13.4. Rest of MEA Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Oncology Biosimilars Industry

• 11.1. Competitive Dashboard
• 11.2. Company Profiles
  • 11.2.1. Teva Pharmaceuticals
  • 11.2.2. STADA Arzneimittel AG
  • 11.2.3. Shanghai Henlius Biotech
  • 11.2.4. Sandoz (Novartis)
  • 11.2.5. Samsung Bioepis
  • 11.2.6. Pfizer
  • 11.2.7. Pfenex Inc.
  • 11.2.8. Mylan
  • 11.2.9. Innovent Biologics
  • 11.2.10. Dr. Reddy's Laboratories
  • 11.2.11. Celltrion Healthcare
  • 11.2.12. Biocon
  • 11.2.13. Apotex
  • 11.2.14. Amgen
  • 11.2.15. Accord Healthcare

12. 360 Degree Analyst View

13. Appendix

• 13.1. Research Methodology
• 13.2. References
• 13.3. Abbreviations
• 13.4. Disclaimer
• 13.5. Contact Us

관련자료